title: Nitric oxide inhibition of IGF-1 stimulated proteoglycan synthesis: role of cGMP.
abstract: Insulin-like growth factor (IGF-1) is critical for normal development and maintenance of cartilage, however arthritic cartilage responds poorly to IGF-1; part of this insensitivity is mediated by nitric oxide (NO). These studies test if cGMP is responsible for NO dependent insensitivity to IGF-1 in chondrocytes in situ in organ culture and in monolayer culture. Lapine cartilage and chondrocytes in monolayer culture and cartilage from osteoarthritic human knees were used. Tissues were exposed to NO from iNOS induced by IL-1, and proteoglycan synthesis in response to IGF-1 was evaluated in the presence and absence of cGMP dependent protein kinase (PKG) inhibitors. PKG activators inhibited IGF-1 responses in cartilage but not chondrocytes in monolayer. IL-1 stimulated cGMP synthesis in both monolayer and organ cultures. However, PKG inhibitors in cartilage slices but not in monolayer cultures restored response to IGF-1. PKG activity was detected in both fresh and monolayer chondrocytes, confirming this part of the cGMP signal cascade is intact in both of the preparations evaluated. Arthritic cartilage response to IGF-1 was restored by both N(G)-monomethyl-L-arginine inhibition of NO synthesis and PKG inhibitors. The data suggests that cGMP mediated effects are critical to NO actions on chondrocytes in situ in the cartilage matrix and supports a role for cGMP in the pathophysiologic effects of NO in osteoarthritis.
authors.affiliation: The Ferguson Lab, Department of Orthopaedic Surgery, VA Pittsburgh Healthcare System, University of Pittsburgh School of Medicine, MSRC, Pittsburgh, PA 15240, USA. rstuder@pitt.edu
authors.forename: R K
authors.initials: RK
authors.lastname: Studer
authors.forename: K
authors.initials: K
authors.lastname: Decker
authors.forename: S
authors.initials: S
authors.lastname: Melhem
authors.forename: H
authors.initials: H
authors.lastname: Georgescu
mesh_terms: D000818:Animals; D002358:Cartilage, Articular / Q000187:drug effects / Q000378:metabolism*; D002478:Cells, Cultured; D019902:Chondrocytes / Q000187:drug effects / Q000378:metabolism*; D006152:Cyclic GMP / Q000502:physiology*; D017869:Cyclic GMP-Dependent Protein Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000494:pharmacology*; D009569:Nitric Oxide / Q000494:pharmacology*; D009924:Organ Culture Techniques; D011509:Proteoglycans / Q000037:antagonists & inhibitors* / Q000096:biosynthesis; D011817:Rabbits; D019323:omega-N-Methylarginine / Q000494:pharmacology
chemical_list: D004791:Enzyme Inhibitors; D011509:Proteoglycans; D019323:omega-N-Methylarginine; D009569:Nitric Oxide; D007334:Insulin-Like Growth Factor I; D017869:Cyclic GMP-Dependent Protein Kinases; D006152:Cyclic GMP